HaniKushlafMDFAAN, FANA, FAANEM

Neuromuscular Medicine

Neuromuscular Neurologist, Associate Professor, Neurology and Pathology, University of Cincinnati College of Medicine, Director of Neuromuscular Disorders Division , Director of Neuromuscular Research, Neuromuscular Medicine Fellowship Director, Director of UC Muscular Dystrophy Association (MDA) Care Center

Join to view full profile

Dr. Kushlaf is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Connect with other colleagues in the same hospital or clinic
Search all U.S. specialist profiles and refer a patient
Read the latest clinical news and earn CME/CEU credits

See Dr. Kushlaf's full profile

Already have an account?

Office
3113 Bellevue Ave
Cincinnati, OH 45219
Phone+1 513-475-8730

Fax+1 513-475-8033
Is this information wrong?

Summary

Dr. Hani Kushlaf is a neuromuscular neurologist in Cincinnati, OH and is affiliated with multiple hospitals in the area, including the University of Cincinnati Medical Center, and Cincinnati Children's Hospital Medical Center. He received his medical degree from the University of Tripoli School of Medicine and has been in practice for more than 15 years. He also speaks multiple languages, including Arabic. He specializes in neuromuscular medicine and is experienced in muscular dystrophies, myasthenia gravis, Lambert-Eaton Myasthenic Syndrome (LEMS), Late-Onset Pompe Disease, myopathies, amyotrophic lateral sclerosis (ALS), peripheral neuropathies, chronic inflammatory demyelinating polyneuropathy (CIDP), and POEMS neuropathy.

Education & Training

University of CincinnatiPost-Baccalaureate Certificate Program in Clinical and Translational Research, Clinical and Translational Research, 2017 - 2018
Duke University HospitalFellowship, Neuromuscular Medicine (Neurology), 2011 - 2012
Mayo Clinic College of Medicine and Science (Rochester)Fellowship, Neuromuscular Medicine (Neurology), 2010 - 2011
Mayo Clinic College of Medicine and Science (Rochester)Fellowship, Neuromuscular Medicine (Neurology), 2009 - 2010
University of Kentucky College of MedicineChief Residency, Neurology, 2008 - 2009
University of Kentucky College of MedicineResidency, Neurology, 2005 - 2008
University of Tripoli School of MedicineClass of 2002

Certifications & Licensure

OH State Medical License 2012 - 2024
MN State Medical License 2009 - 2012
NC State Medical License 2011 - 2012
American Board of Psychiatry and Neurology Neurology
American Board of Psychiatry and Neurology Neuromuscular Medicine
American Board of Electrodiagnostic MedicineAmerican Board of Electrodiagnostic Medicine-Neuromuscular Ultrasound Certificate of Added Qualification
American Board of Electrodiagnostic MedicineElectrodiagnostic Medicine
The United Council of Neurologic SubspecialtiesClinical Neuromuscular Pathology

Awards, Honors, & Recognition

CastleConnolly Top Doctor CastleConnolly, 2017-2023
President’s Research Initiative Award AANEM, 2022
America's Most Honored Doctors American Registry, 2021
Alpha Omega Alpha Honor Medical Society Alpha Omega Alpha, 2020
America's Most Honored Doctors The American Registry, 2020
Cincy Best Docs CincyMagazine, 2020
On-Time Doctor Award Vitals, 2015, 2018, 2020
Patients’ Choice Award Vitals Patients Choice, 2008, 2018, 2020
Who's Who in America Marquis Who'sWho, 2019
America's Most Honored Professionals The American Registry, 2019
Top Neurologist Ohio Magazine, 2019
Compassionate Doctor Recognition Vitals, 2018
President’s Award AANEM, 2017
Junior Member Recognition Award American Association of Neuromuscular and Electrodiagnostic Medicine, 2012
CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory EMR, Epic Systems Corporation, 2012
Join now to see all

Clinical Trials

Pharmacokinetics of Alglucosidase Alfa in Patients With Pompe Disease Start of enrollment: 2014 Nov 03
Completed
Phase 4
Safety and Efficacy Evaluation of Repeat neoGAA Dosing in Late Onset Pompe Disease Patients. Start of enrollment: 2013 Aug 19
Completed
Phase 1
BeatMG: Phase II Trial of Rituximab In Myasthenia Gravis Start of enrollment: 2014 May 01
Completed
Phase 2
Patient Assisted Intervention for Neuropathy: Comparison of Treatment in Real Life Situations Start of enrollment: 2014 Oct 01
Completed
Phase 4
A Study of HyQvia and Gammagard Liquid (Kiovig) in Adults With Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP) Start of enrollment: 2015 Dec 15
Completed
Phase 3
Study to Compare the Efficacy and Safety of Enzyme Replacement Therapies Avalglucosidase Alfa and Alglucosidase Alfa Administered Every Other Week in Patients With Late-onset Pompe Disease Who Have Not Been Previously Treated for Pompe Disease Start of enrollment: 2016 Nov 02
Completed
Phase 3
Study to Evaluate Amifampridine Phosphate in Patients With MuSK-MG Start of enrollment: 2018 Apr 18
Completed
Phase 3
Long Term Safety Study of Amifampridine Phosphate in MuSK-MG (Muscle Specific Tyrosine Kinase Myasthenia Gravis) Start of enrollment: 2018 Jul 01
Active, not recruiting
Phase 3
A Study Comparing ATB200/AT2221 With Alglucosidase Alfa/Placebo in Adult Subjects With Late-onset Pompe Disease Start of enrollment: 2018 Dec 04
Completed
Phase 3
A Study to Evaluate the Safety, Tolerability, Efficacy, Pharmacokinetics and Pharmacodynamics of M281 Administered to Adults With Generalized Myasthenia Gravis Start of enrollment: 2019 Apr 10
Completed
Phase 2
An Extension Study of MOM-M281-004 to Evaluate the Safety, Tolerability, and Efficacy of M281 Administered to Patients With Generalized Myasthenia Gravis Start of enrollment: 2019 Aug 06
Terminated
Phase 2
Safety and Efficacy Study of Ravulizumab in Adults With Generalized Myasthenia Gravis Start of enrollment: 2019 Mar 26
Completed
Phase 3
A Study to Assess the Long-term Safety and Efficacy of ATB200/AT2221 in Adult Subjects With LOPD Start of enrollment: 2019 Dec 18
Active, not recruiting
Phase 3
A Study of TAK-079 in People With Generalized Myasthenia Gravis Start of enrollment: 2020 Jan 14
Completed
Phase 2
A Study to Assess the Long-term Safety and Efficacy of a Subcutaneous Formulation of Efgartigimod in Adults With Chronic Inflammatory Demyelinating Polyneuropathy (CIDP, an Autoimmune Disorder That Affects the Peripheral Nerves) Start of enrollment: 2020 Sep 18
Active, not recruiting
Phase 2
A Study to Assess the Safety and Efficacy of a Subcutaneous Formulation of Efgartigimod in Adults With Chronic Inflammatory Demyelinating Polyneuropathy (CIDP, an Autoimmune Disorder That Affects the Peripheral Nerves) Start of enrollment: 2020 Apr 15
Completed
Phase 2
Myasthenia Gravis Inebilizumab Trial Start of enrollment: 2020 Aug 30
Active, not recruiting
Phase 3
Phase 2 Study of EDG-5506 in Becker Muscular Dystrophy (GRAND CANYON) Start of enrollment: 2022 Jul 06
Recruiting
Phase 2
Safety and Efficacy of Pitolisant on Excessive Daytime Sleepiness and Other Non-Muscular Symptoms in Patients With Myotonic Dystrophy Type 1 Start of enrollment: 2021 Jun 28
Active, not recruiting
Phase 2
Join now to see all

Publications & Presentations

PubMed

Minimal clinically important differences in six-minute walking distance in late-onset Pompe disease.
Kristl G Claeys, Syed Raza, Noemi Hummel, Simon Shohet, Ian Keyzor, Agnieszka Kopiec, Ryan Graham, Brian Fox, Benedikt Schoser, Hani Kushlaf> ;Orphanet Journal of Rare Diseases. 2024 Apr 11
Efficacy of ravulizumab in patients with generalized myasthenia gravis by time from diagnosis: A post hoc subgroup analysis of the CHAMPION MG study.
James F Howard Jr, Tuan Vu, Renato Mantegazza, Hani Kushlaf, Shigeaki Suzuki, Heinz Wiendl, Kathleen N Beasley, Serena Liao, Andreas Meisel> ;Muscle & Nerve. 2024 May 1
7 citations
Efficacy and Safety of Avalglucosidase Alfa in Patients With Late-Onset Pompe Disease After 97 Weeks: A Phase 3 Randomized Clinical Trial.
Priya S Kishnani, Jordi Diaz-Manera, Antonio Toscano, Paula R Clemens, Shafeeq Ladha, Kenneth I Berger, Hani Kushlaf, Volker Straub, Gerson Carvalho, Tahseen Mozaffar,...> ;JAMA Neurology. 2023 Jun 1
3 citations
Provisional practice recommendation for the management of myopathy in VCP-associated multisystem proteinopathy.
Bhaskar Roy, Allison Peck, Teresinha Evangelista, Gerald Pfeffer, Leo Wang, Jordi Diaz-Manera, Manisha Korb, Matthew P Wicklund, Margherita Milone, Miriam Freimer, Han...> ;Annals of Clinical and Translational Neurology. 2023 May 1
5 citations
Current status of clinical outcome measures in inclusion body myositis: a systematised review.
Bhaskar Roy, Matteo Lucchini, James B Lilleker, Namita A Goyal, Elie Naddaf, Brittany Adler, Lindsay N Alfano, Georgia A Malandraki, Kendrea L Focht Garand, David Moch...> ;Clinical and Experimental Rheumatology. 2023 Mar 1
1 citations
The applicability of the myasthenia gravis patient registry data to disease burden and medication changes in clinical practice.
Hani Kushlaf> ;Muscle & Nerve. 2022 Oct 1
17 citations
Genotype-phenotype correlations in valosin-containing protein disease: a retrospective muticentre study.
Marianela Schiava, Chiseko Ikenaga, Rocío Nur Villar-Quiles, Marta Caballero-Ávila, Ana Topf, Ichizo Nishino, Virginia Kimonis, Bjarne Udd, Benedikt Schoser, Edmar Zan...> ;Journal of Neurology, Neurosurgery, and Psychiatry. 2022 Jul 27
30 citations
Safety and efficacy of cipaglucosidase alfa plus miglustat versus alglucosidase alfa plus placebo in late-onset Pompe disease (PROPEL): an international, randomised, d...
Benedikt Schoser, Mark Roberts, Barry J. Byrne, Sheela Sitaraman, Hai Jiang, Pascal Laforet, Antonio Toscano, Jeff Castelli, Jordi Díaz-Manera, Mitchell Goldman, Ans T...> ;The Lancet. Neurology. 2021 Dec 1
48 citations
Safety and efficacy of avalglucosidase alfa versus alglucosidase alfa in patients with late-onset Pompe disease (COMET): a phase 3, randomised, multicentre trial.
Jordi Diaz-Manera, Priya S. Kishnani, Hani Kushlaf, Shafeeq Ladha, Tahseen Mozaffar, Volker Straub, Antonio Toscano, Ans T. van der Ploeg, Kenneth I. Berger, Paula R. ...> ;The Lancet. Neurology. 2021 Dec 1
Development of a standard of care for patients with valosin-containing protein associated multisystem proteinopathy.
Korb M, Peck A, Alfano LN, Berger KI, James MK, Ghoshal N, Healzer E, Henchcliffe C, Khan S, Mammen PPA, Patel S, Pfeffer G, Ralston SH, Roy B, Seeley WW, Swenson A, M...> ;Orphanet journal of rare diseases. 2022-01-29
How does rituximab fit in the treatment algorithm of myasthenia gravis
Hani Kushlaf, Yuebing Li> ;Muscle & Nerve. 2021 Sep 21
Extracellular Amyloid Deposition in Sporadic Inclusion Body Myositis: Further Insights
Hani Kushlaf, Kariem Ezzat> ;Muscle & Nerve. 2021 Aug 15
14 citations
Training in Neurology: How Lessons Learned on Teaching, Well-being and Telemedicine During the COVID-19 Pandemic Can Shape the Future of Neurology Education.
Stefano Sandrone, Dara V.F. Albert, S. Richard Dunham, Jessica Kraker, Ika Noviawaty, Hani Kushlaf> ;Neurology. 2021 Apr 28
4 citations
Genetic Modifiers of Hereditary Neuromuscular Disorders and Cardiomyopathy.
Sholeh Bazrafshan, Hani Kushlaf, Mashhood Kakroo, John G. Quinlan, Richard C. Becker, Sakthivel Sadayappan> ;Cells. 2021 Feb 8
Immune profiling beyond antibodies in double seronegative and acetylcholine receptor antibody positive myasthenia gravis: What do we learn?
Hani Kushlaf> ;Muscle & Nerve. 2021 Jan 19
17 citations
Patient Assisted Intervention for Neuropathy: Comparison of Treatment in Real Life Situations (PAIN-CONTRoLS): Bayesian Adaptive Comparative Effectiveness Randomized T...
Richard J. Barohn, Byron J. Gajewski, Mamatha Pasnoor, Alexandra R. Brown, Laura Herbelin, Kim S. Kimminau, Dinesh Pal Mudaranthakam, Omar Jawdat, Mazen M. Dimachkie, ...> ;JAMA Neurology. 2021 Jan 1
Cystinosis myopathy: Searching for optimal clinical outcome measures.
Hani Kushlaf> ;Muscle & Nerve. 2020 Sep 22
1 citations
Toxin-Induced Channelopathies, Neuromuscular Junction Disorders, and Myopathy.
Jacqueline Janecek, Hani Kushlaf> ;Neurologic Clinics. 2020 Sep 12
17 citations
COVID-19 in muscle-specific kinase myasthenia gravis: A case report.
Hani Kushlaf> ;Muscle & Nerve. 2020 Aug 2
Diving into the Heterogeneity of Inclusion Body Myositis.
Hani Kushlaf> ;Muscle & Nerve. 2020 Apr 30
3 citations
The evidence is stacked against thymectomy in MuSK myasthenia gravis
Hani Kushlaf, Yuebing Li> ;Muscle & Nerve. 2019 Apr 1
Peripheral Neuropathy and the Ceruloplasmin Gene
Hani Kushlaf> ;Annals of Internal Medicine. 2019 Feb 19
7 citations
Neurologic and neuroscience education: Mitigating neurophobia to mentor health care providers.
Stefano Sandrone, Jimmy V. Berthaud, Miguel Chuquilin, Jacquelyne Cios, Pritha Ghosh, Rachel Gottlieb-Smith, Hani Kushlaf, Sneha Mantri, Neil Masangkay, Daniel L. Menk...> ;Neurology. 2019 Jan 22
10 citations
New onset of seropositive generalized myasthenia gravis following intravesical bacille Calmette-Guerin treatment for bladder cancer: A case study
Long Davalos, Hani Kushlaf> ;Muscle & Nerve. 2019 Jan 1
6 citations
Needle electromyography practice patterns in patients taking novel oral anticoagulants: A survey-based study.
Ikjae Lee, Hani Kushlaf> ;Muscle & Nerve. 2018 Mar 25
Join now to see all

Journal Articles

Ultrasound diagnosis of bony nerve entrapment: Case series and literature review.
Erra C, Granata G, Liotta G, Podnar S, Giannini M, Kushlaf H, Hobson-Webb LD, Leversedge FJ, Martinoli C, Padua L., Muscle Nerve

Press Mentions

Researchers Find a New Treatment for Rare Muscular DiseaseApril 16th, 2021
AAN 2021: COMET Findings Suggest Avalglucosidase Alfa Could Become New Standard for Late-Onset Pompe Disease Compared with current standard treatment, it offered at least as good functional outcomes with a better safety profileAugust 1st, 2021
For Springfield Township man, hope comes from an ice bucketFebruary 12th, 2021
Join now to see all

Committees

Member, American Board of Electrodiagnostic Medicine Maintenance of Certification Program Examination Committee 2018 - Present
Member, American Association of Neuromuscular and Electrodiagnostic Medicine- Neuromsucular Self-Assessment Committee 2016 - 2020
Member, American Association of Neuromuscular and Electrodiagnostic Medicine Electrodiagnostic Self-Assessment Committee 2013 - 2016